MMP2 and breast cancer: For example, it was found that EMT-associated markers, including Vimentin and MMP2, were increased in residual breast cancers after conventional therapy (Creighton et al., 2009), suggesting that breast cancer cells with molecular signatures associated with EMT may be more resistant to endocrine therapy (letrozole) or chemotherapy (docetaxel).